BASEL (dpa-AFX) - Novartis AG (NVS) Thursday announced that the FDA has
granted Breakthrough Therapy designation to Scemblix for treating adult patients
with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
or CML in chronic phase. This is the third Breakthrough Therapy designation
assigned to Scemblix.

The designation is based on positive data from the Phase III ASC4FIRST study, in
which Scemblix met both primary endpoints, compared to imatinib alone. In
comparison with standard-of-care drugs, Scemblix demonstrated a favorable safety
and tolerability profile.

Breakthrough Therapy designation is usually to a drug compound that targets a
serious or life-threatening disease and demonstrates a potential substantial
improvement over existing therapies.

Currently, shares are at $101.42, up 1.20 percent from the previous close of
$100.21 on a volume of 176,838.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX